[Present resistance status of Staphylococcus aureus under specific consideration of the antibiotics virgimycia, cephalothin and fusidic acid].
D000328:Adult; D000667:Ampicillin / Q000494:pharmacology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001414:Bacitracin / Q000494:pharmacology; D002512:Cephalothin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D002648:Child; D002701:Chloramphenicol / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D005672:Fusidic Acid / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009355:Neomycin / Q000494:pharmacology; D009582:Nitrofurantoin / Q000494:pharmacology; D009827:Oleandomycin / Q000494:pharmacology; D010400:Penicillin G / Q000494:pharmacology; D010403:Penicillin Resistance; D010404:Penicillin V / Q000031:analogs & derivatives / Q000494:pharmacology; D013210:Staphylococcus / Q000187:drug effects*; D013307:Streptomycin / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology*; D013752:Tetracycline / Q000494:pharmacology; D014769:Virginiamycin / Q000009:adverse effects / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D013449:Sulfonamides; D014769:Virginiamycin; D001414:Bacitracin; D005672:Fusidic Acid; D004917:Erythromycin; D002701:Chloramphenicol; D000667:Ampicillin; D009582:Nitrofurantoin; D013752:Tetracycline; D009355:Neomycin; D009827:Oleandomycin; D010400:Penicillin G; D002512:Cephalothin; D013307:Streptomycin; D010404:Penicillin V
Die derzeitige Resistenzlage bei Staphylococcus aureus unter besonderer Berücksichtigung der Antibiotica Virgimycin, Cefalotin und Fusidinsäure.